Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: No intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 49 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Venous Thrombosis
Interventions: Gore Viabahn Heparin Coated Stent; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions: There is no intervention in this study; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Mild to Moderately Active Ulcerative Colitis
Interventions: Polyphenon E®, Placebo Oral Tablet; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Venous Leg Ulcer
Interventions: Weekly wound spray with components 1 and 2 of the compound HP802-247; Biological
Lead sponsor: Atlantic Health System; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Summit, New Jersey

Conditions: Colitis, Ulcerative, Obesity
Interventions: Phentermine-Topiramate, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions: Curcumin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 8 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes, Type 1, Diabetes, Type 2, Foot Ulcer, Diabetic
Interventions: Bacitracin, AmeriGel®, Vitamin C; Drug · Dietary Supplement
Lead sponsor: Susan Hassenbein; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: Vorinostat, Ustekinumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leg Ulcers, Venous Ulcers, Varicose Ulcers
Interventions: FOOTFIT; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 55 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Diabetic Foot Ulcer
Interventions: AutoloGel, Usual and Customary Care; Device · Other
Lead sponsor: Cytomedix; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Upper GI Bleeding, Bleeds Gastric, Bleed Ulcer, Hemorrhage Gastric, Hemorrhage; Ulcer
Interventions: Metoclopramide 10mg, Saline; Drug
Lead sponsor: Mercy Health System; Network
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rockford, Illinois

Conditions: Healthy, Skin Ulcer
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pyoderma Gangrenosum
Interventions: Platelet rich plasma therapy; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions: Mirikizumab, Anti-TNF agents, anti-integrin antibodies, IL-12, IL-23; Drug
Lead sponsor: Specialty Networks Research.; Network
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Sun City, Arizona • Tucson, Arizona • Glenview, Illinois + 10 more

Conditions: Diabetic Foot Ulcer
Interventions: gentamicin-collagen sponge, Levofloxacin; Drug
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pasadena, Maryland

Conditions: Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions: Allograft; Other
Lead sponsor: Tides Medical; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Fresno, California • Los Angeles, California • Vista, California + 5 more

Conditions: Venous Leg Ulcer
Interventions: 0.1% TR 987, Placebo gel; Drug
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 9
States / cities: Los Angeles, California • North Miami Beach, Florida • Pembroke Pines, Florida + 6 more

Conditions: Ulcerative Colitis (UC)
Interventions: ALTB-268, Placebo; Biological · Other
Lead sponsor: AltruBio Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-healing Wound, Non-Healing Ulcer of Skin
Interventions: Omeza Products Used in Combination; Combination Product
Lead sponsor: Omeza, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Santa Fe, New Mexico

Conditions: Colitis, Ulcerative
Interventions: LYC-30937-EC, Placebo; Drug
Lead sponsor: Lycera Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 26
States / cities: Little Rock, Arkansas • Long Beach, California • Mission Hills, California + 20 more

Conditions: Venous Leg Ulcers
Interventions: Unite Biomatrix; Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Warren, Pennsylvania

Search by objective public record fields.

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

Trial of Compassionate Use of hp802-247 to Treat Venous Leg Ulcers in Subjects Who Have Failed Multiple Other Healing Technologies

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

Curcumin in Pediatric Inflammatory Bowel Disease

The Relationship of Hemoglobin A1c and Diabetic Wound Healing

Complications and Outcomes of Pouch Excision

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

Physical Activity Interventions for Leg Ulcer Patients

Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.

Metoclopramide in Upper Gastrointestinal Bleed

Pathophysiology of Chronic Wounds

Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum

INSIGHT-IBD Pragmatic Study

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers